Kazutaka Mori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kazutaka Mori has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
Takafumi Suda
15 shared publications- Yuzo Suzuki
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
13 shared publications - Tomoyuki Fujisawa
Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
12 shared publications - Hideki Yasui
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
9 shared publications - Masato Karayama
Hamamatsu University School of Medicine
9 shared publications - Hironao Hozumi
Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
8 shared publications
Latest Publications
- 11 September 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64  (6)
Serum GDF15 adds prognostic value to forced vital capacity in fibrotic interstitial lung disease
- 11 September 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64  (6)
Serum GDF15 adds prognostic value to forced vital capacity in fibrotic interstitial lung disease
- 1 February 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 8  (1) , e250190
Clinical Characteristics and Prevalence of Apical Scarring at Chest CT in a Healthy Population
In individuals without underlying causes known to cause pleuroparenchymal fibroelastosis, apical scarring at chest CT was more prevalent with age, associated with a lean body habitus, and more likely to progress over time when baseline lesions were more extensive.
- 1 February 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 8  (1) , e250190
Clinical Characteristics and Prevalence of Apical Scarring at Chest CT in a Healthy Population
In individuals without underlying causes known to cause pleuroparenchymal fibroelastosis, apical scarring at chest CT was more prevalent with age, associated with a lean body habitus, and more likely to progress over time when baseline lesions were more extensive.
- Open Access
- 10 August 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42  (23) , 2780-2789
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
PURPOSE: We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in patients receiving carboplatin-containing chemotherapy. PATIENTS AND METHODS: Chemotherapy-naïve patients scheduled to receive carboplatin (AUC ≥5) were randomly assigned to receive either olanzapine 5 mg once daily (olanzapine group) or placebo (placebo group) in combination with aprepitant, a 5-HT3 RA, and dexamethasone. The primary end point was the complete response (CR; no vomiting and no rescue therapy) rate in the overall phase (0-120 hours). Secondary end points included the proportion of patients free of nausea and safety. RESULTS: In total, 355 patients (78.6% male, median age 72 years, 100% thoracic cancer), including 175 and 180 patients in the olanzapine and placebo groups, respectively, were evaluated. The overall CR rate was 86.9% in the olanzapine group versus 80.6% in the placebo group. The intergroup difference in the overall CR rate was 6.3% (95% CI, –1.3 to 13.9). The proportions of patients free of chemotherapy-induced nausea in the overall (88.6% in the olanzapine group v 75.0% in the placebo group) and delayed (89.7% v 75.6%, respectively) phases were significantly higher in the olanzapine group than in the placebo group (both P < .001). Somnolence was observed in 43 (24.6%) and 41 (22.9%) patients in the olanzapine and placebo groups, respectively, and no events were grade ≥3 in severity. CONCLUSION: The addition of olanzapine was not associated with a significant increase in the overall CR rate. Regarding the prevention of nausea, adding olanzapine provided better control in patients receiving carboplatin-containing chemotherapy, which needs further exploration.
- 10 August 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42  (23) , 2780-2789
Open AccessOlanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
PURPOSE: We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in patients receiving carboplatin-containing chemotherapy. PATIENTS AND METHODS: Chemotherapy-naïve patients scheduled to receive carboplatin (AUC ≥5) were randomly assigned to receive either olanzapine 5 mg once daily (olanzapine group) or placebo (placebo group) in combination with aprepitant, a 5-HT3 RA, and dexamethasone. The primary end point was the complete response (CR; no vomiting and no rescue therapy) rate in the overall phase (0-120 hours). Secondary end points included the proportion of patients free of nausea and safety. RESULTS: In total, 355 patients (78.6% male, median age 72 years, 100% thoracic cancer), including 175 and 180 patients in the olanzapine and placebo groups, respectively, were evaluated. The overall CR rate was 86.9% in the olanzapine group versus 80.6% in the placebo group. The intergroup difference in the overall CR rate was 6.3% (95% CI, –1.3 to 13.9). The proportions of patients free of chemotherapy-induced nausea in the overall (88.6% in the olanzapine group v 75.0% in the placebo group) and delayed (89.7% v 75.6%, respectively) phases were significantly higher in the olanzapine group than in the placebo group (both P < .001). Somnolence was observed in 43 (24.6%) and 41 (22.9%) patients in the olanzapine and placebo groups, respectively, and no events were grade ≥3 in severity. CONCLUSION: The addition of olanzapine was not associated with a significant increase in the overall CR rate. Regarding the prevention of nausea, adding olanzapine provided better control in patients receiving carboplatin-containing chemotherapy, which needs further exploration.
- Open Access
- 24 February 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 224, 107577
Radiological and histopathological features and treatment response by subtypes of interstitial pneumonia with autoimmune features: A prospective, multicentre cohort study
- 24 February 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 224, 107577
Open AccessRadiological and histopathological features and treatment response by subtypes of interstitial pneumonia with autoimmune features: A prospective, multicentre cohort study
- 7 February 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 223, 107542
Neutrophil–lymphocyte ratio being associated with mortality risk in patients receiving antifibrotic therapy
- 7 February 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 223, 107542
Neutrophil–lymphocyte ratio being associated with mortality risk in patients receiving antifibrotic therapy
- Open Access
- 1 March 2021
- Published by Elsevier in Radiology Case Reports
- Vol. 16  (3) , 714-717
Extrinsic compression of the left main coronary artery: A rare cause of cardiogenic shock
- 1 March 2021
- Published by Elsevier in Radiology Case Reports
- Vol. 16  (3) , 714-717
Open AccessExtrinsic compression of the left main coronary artery: A rare cause of cardiogenic shock
- Open Access
- 22 February 2021
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 21  (1) , 1-9
Cluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival
Background: The precise classification of idiopathic interstitial pneumonia (IIP) is essential for selecting treatment as well as estimating clinical outcomes; however, this is sometimes difficult in clinical practice. Therefore, cluster analysis was used to identify the clinical phenotypes of IIPs, and its usefulness for predicting clinical outcomes was evaluated. Methods: Cluster analysis was performed using clinical features including patients’ demographics; histories; pulmonary function test data; and laboratory, physical and radiological findings. Results: In 337 patients with IIPs, four clusters were identified: Cluster I, in which > 80% of the patients had autoimmune features; Cluster II, which had the lowest rate of smoking, the lowest percent predicted forced vital capacity (%FVC) and the lowest body mass index (BMI); Cluster III, which had the highest rate of smoking, the highest rate of dust exposure, the second lowest %FVC and normal BMI; and Cluster IV, which exhibited maintenance of %FVC and normal BMI. Cluster IV had significantly longer overall survival than Clusters II and III. Clusters I and III had significantly longer overall survival than Cluster II. Clusters II and III had a significantly higher cumulative incidence of acute exacerbation than Cluster IV. Conclusion: Cluster analysis using clinical features identified four clinical phenotypes of IIPs, which may be useful for predicting the risk of acute exacerbation and overall survival.
- 22 February 2021
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 21  (1) , 1-9
Open AccessCluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival
Background: The precise classification of idiopathic interstitial pneumonia (IIP) is essential for selecting treatment as well as estimating clinical outcomes; however, this is sometimes difficult in clinical practice. Therefore, cluster analysis was used to identify the clinical phenotypes of IIPs, and its usefulness for predicting clinical outcomes was evaluated. Methods: Cluster analysis was performed using clinical features including patients’ demographics; histories; pulmonary function test data; and laboratory, physical and radiological findings. Results: In 337 patients with IIPs, four clusters were identified: Cluster I, in which > 80% of the patients had autoimmune features; Cluster II, which had the lowest rate of smoking, the lowest percent predicted forced vital capacity (%FVC) and the lowest body mass index (BMI); Cluster III, which had the highest rate of smoking, the highest rate of dust exposure, the second lowest %FVC and normal BMI; and Cluster IV, which exhibited maintenance of %FVC and normal BMI. Cluster IV had significantly longer overall survival than Clusters II and III. Clusters I and III had significantly longer overall survival than Cluster II. Clusters II and III had a significantly higher cumulative incidence of acute exacerbation than Cluster IV. Conclusion: Cluster analysis using clinical features identified four clinical phenotypes of IIPs, which may be useful for predicting the risk of acute exacerbation and overall survival.
- 1 November 2020
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 60  (5) , 933-940
Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians' View
- 1 November 2020
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 60  (5) , 933-940
Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians' View
- 1 May 2020
- Published by Elsevier in Lung Cancer
- Vol. 143, 47-54
Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer
- 1 May 2020
- Published by Elsevier in Lung Cancer
- Vol. 143, 47-54
Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer